TSE:LABS

MediPharm Labs Competitors

C$0.47

-0.01 (-2.08 %)

(As of 04/16/2021 05:41 PM ET)

Add

Compare

Today's Range

C$0.46

Now: C$0.47▼

C$0.48

50-Day Range

C$0.46

MA: C$0.51▼

C$0.74

52-Week Range

C$0.45

Now: C$0.47▼

C$2.25

Volume1.09 million shs

Average Volume2.66 million shs

Market CapitalizationC$121.24 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

MediPharm Labs (TSE:LABS) Vs. RIV, WLLW, KHRN, DN, META, and NRTH

Should you be buying LABS stock or one of its competitors? Companies in the industry of "drug manufacturers—specialty & generic" are considered alternatives and competitors to MediPharm Labs, including RIV Capital (RIV), Willow Biosciences Inc. (WLLW.TO) (WLLW), Khiron Life Sciences (KHRN), Delta 9 Cannabis (DN), Meta Growth (META), and 48North Cannabis (NRTH).

MediPharm Labs vs. RIV Capital Stock

MediPharm Labs (TSE:LABS) and RIV Capital (TSE:RIV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for MediPharm Labs and RIV Capital, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediPharm Labs	0	2	0	2	3.00
RIV Capital	0	1	0	0	2.00

MediPharm Labs presently has a consensus target price of C$1.53, suggesting a potential upside of 225.53%. RIV Capital has a consensus target price of C$4.00, suggesting a potential upside of 90.48%. Given MediPharm Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe MediPharm Labs is more favorable than RIV Capital.

Profitability

This table compares MediPharm Labs and RIV Capital's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MediPharm Labs	N/A	N/A	N/A
RIV Capital	N/A	N/A	N/A

Earnings & Valuation

This table compares MediPharm Labs and RIV Capital's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediPharm Labs	C$36.01 million	3.37	C$-123,815,040.00	C($0.48)	-0.98
RIV Capital	C$15.44 million	19.03	C$-106,223,568.00	C($0.76)	-2.77

RIV Capital has lower revenue, but higher earnings than MediPharm Labs. RIV Capital is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Summary

MediPharm Labs beats RIV Capital on 6 of the 8 factors compared between the two stocks.

MediPharm Labs vs. Willow Biosciences Inc. (WLLW.TO) Stock

MediPharm Labs (TSE:LABS) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Earnings and Valuation

This table compares MediPharm Labs and Willow Biosciences Inc. (WLLW.TO)'s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediPharm Labs	C$36.01 million	3.37	C$-123,815,040.00	C($0.48)	-0.98
Willow Biosciences Inc. (WLLW.TO)	C$10,000.00	16,271.38	C$-51,032,952.00	C($0.41)	-3.19

Willow Biosciences Inc. (WLLW.TO) has lower revenue, but higher earnings than MediPharm Labs. Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MediPharm Labs and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MediPharm Labs	N/A	N/A	N/A
Willow Biosciences Inc. (WLLW.TO)	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations for MediPharm Labs and Willow Biosciences Inc. (WLLW.TO), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediPharm Labs	0	2	0	2	3.00
Willow Biosciences Inc. (WLLW.TO)	0	0	0	0	N/A

MediPharm Labs currently has a consensus target price of C$1.53, suggesting a potential upside of 225.53%. Willow Biosciences Inc. (WLLW.TO) has a consensus target price of C$2.25, suggesting a potential upside of 70.45%. Given MediPharm Labs' higher possible upside, research analysts plainly believe MediPharm Labs is more favorable than Willow Biosciences Inc. (WLLW.TO).

Summary

MediPharm Labs beats Willow Biosciences Inc. (WLLW.TO) on 4 of the 7 factors compared between the two stocks.

MediPharm Labs vs. Khiron Life Sciences Stock

MediPharm Labs (TSE:LABS) and Khiron Life Sciences (CVE:KHRN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Profitability

This table compares MediPharm Labs and Khiron Life Sciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MediPharm Labs	N/A	N/A	N/A
Khiron Life Sciences	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for MediPharm Labs and Khiron Life Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediPharm Labs	0	2	0	2	3.00
Khiron Life Sciences	0	0	0	0	N/A

MediPharm Labs currently has a consensus target price of C$1.53, indicating a potential upside of 225.53%. Khiron Life Sciences has a consensus target price of C$1.20, indicating a potential upside of 135.29%. Given MediPharm Labs' higher possible upside, research analysts plainly believe MediPharm Labs is more favorable than Khiron Life Sciences.

Valuation and Earnings

This table compares MediPharm Labs and Khiron Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediPharm Labs	C$36.01 million	3.37	C$-123,815,040.00	C($0.48)	-0.98
Khiron Life Sciences	C$8.01 million	9.56	C$-39,493,921.00	C($0.26)	-1.94

Khiron Life Sciences has lower revenue, but higher earnings than MediPharm Labs. Khiron Life Sciences is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Summary

MediPharm Labs beats Khiron Life Sciences on 4 of the 7 factors compared between the two stocks.

MediPharm Labs vs. Delta 9 Cannabis Stock

Delta 9 Cannabis (TSE:DN) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Delta 9 Cannabis and MediPharm Labs' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delta 9 Cannabis	C$52.05 million	1.14	C$-7,346,808.00	C($0.07)	-8.06
MediPharm Labs	C$36.01 million	3.37	C$-123,815,040.00	C($0.48)	-0.98

Delta 9 Cannabis has higher revenue and earnings than MediPharm Labs. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Delta 9 Cannabis and MediPharm Labs, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delta 9 Cannabis	0	0	0	1	4.00
MediPharm Labs	0	2	0	2	3.00

Delta 9 Cannabis currently has a consensus target price of C$1.10, indicating a potential upside of 89.66%. MediPharm Labs has a consensus target price of C$1.53, indicating a potential upside of 225.53%. Given MediPharm Labs' higher probable upside, analysts clearly believe MediPharm Labs is more favorable than Delta 9 Cannabis.

Profitability

This table compares Delta 9 Cannabis and MediPharm Labs' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Delta 9 Cannabis	N/A	N/A	N/A
MediPharm Labs	N/A	N/A	N/A

MediPharm Labs vs. Meta Growth Stock

MediPharm Labs (TSE:LABS) and Meta Growth (CVE:META) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Valuation and Earnings

This table compares MediPharm Labs and Meta Growth's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediPharm Labs	C$36.01 million	3.37	C$-123,815,040.00	C($0.48)	-0.98
Meta Growth	C$60.96 million	0.54	C$-50,412,840.00	C($0.21)	-0.66

Meta Growth has higher revenue and earnings than MediPharm Labs. MediPharm Labs is trading at a lower price-to-earnings ratio than Meta Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MediPharm Labs and Meta Growth's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MediPharm Labs	N/A	N/A	N/A
Meta Growth	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for MediPharm Labs and Meta Growth, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediPharm Labs	0	2	0	2	3.00
Meta Growth	0	0	0	0	N/A

MediPharm Labs currently has a consensus target price of C$1.53, suggesting a potential upside of 225.53%. Given MediPharm Labs' higher possible upside, equities research analysts clearly believe MediPharm Labs is more favorable than Meta Growth.

Summary

Meta Growth beats MediPharm Labs on 4 of the 7 factors compared between the two stocks.

MediPharm Labs vs. 48North Cannabis Stock

MediPharm Labs (TSE:LABS) and 48North Cannabis (CVE:NRTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Profitability

This table compares MediPharm Labs and 48North Cannabis' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MediPharm Labs	N/A	N/A	N/A
48North Cannabis	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for MediPharm Labs and 48North Cannabis, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediPharm Labs	0	2	0	2	3.00
48North Cannabis	0	0	0	0	N/A

MediPharm Labs currently has a consensus target price of C$1.53, indicating a potential upside of 225.53%. Given MediPharm Labs' higher probable upside, analysts clearly believe MediPharm Labs is more favorable than 48North Cannabis.

Valuation and Earnings

This table compares MediPharm Labs and 48North Cannabis' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediPharm Labs	C$36.01 million	3.37	C$-123,815,040.00	C($0.48)	-0.98
48North Cannabis	C$17.36 million	1.84	C$-52,460,873.00	C($0.26)	-0.61

48North Cannabis has lower revenue, but higher earnings than MediPharm Labs. MediPharm Labs is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

MediPharm Labs beats 48North Cannabis on 4 of the 7 factors compared between the two stocks.